logo
Night owls tend to have more health risks than early birds—including cognitive decline, new study finds

Night owls tend to have more health risks than early birds—including cognitive decline, new study finds

Yahoo02-06-2025
Night owls—people whose natural body clock, or chronotype, skews to late sleep and wake times—are already forced to wake up too early for office jobs and to deal with derision from early birds. And now comes a new affront: research concluding that they appear to decline faster, cognitively, than morning people.
To look into this, dementia researcher Ana Wenzler at the University of Groningen in the Netherlands analyzed sleep-based questionnaires through a large national study, BIRD-NL Project. She was able to determine people's chronotypes and found that 52% were morning people, 44% intermediate, and only about 5% night owls—different from the general global population breakdown, where typically 30% are night owls, 40% early birds, and the rest in between.
Next, Wenzler looked at the results of a cognitive function test over a 10-year period to see how the scores differed at the end of the decade.
Her conclusion was that evening people saw faster cognitive decline. But every night owl may not have the same risk.
'We found that 25% of the effect was due to lower sleep quality and smoking,' Wenzler tells Fortune. 'So, having a healthy lifestyle could lower the negative effect of having a late chronotype a bit.'
She says that, for this study, she only looked into the executive function of the brain, so more research is needed into how chronotype affects memory, language, and other cognitive aspects.
But the increased risk here, interestingly, was found mostly in highly educated people. 'That probably has to do with their sleep rhythm,' Wenzler said in a news release. 'They are often people who have to go back to work early in the morning and are therefore more likely to sleep too short, giving their brains too little rest.'
This tracks with a previous body of research showing that night owls, compared with early risers, face various health risks—a 30% higher risk of diabetes, nearly double the odds of depression and other psychological disorders, increased heart disease risk, and a 10% higher all-cause mortality risk.
'All of this evidence, to me at least, impresses the fact that when we do not sleep in harmony with our chronotype, the ensuing sleep disruption that unfolds has consequences,' Matt Walker, a professor of neuroscience and psychology at the University of California, Berkeley, and founder and director of the Center for Human Sleep Science, previously told Fortune.
He added, 'There is vast variability in chronotype, and it's important to sleep in harmony with yours.' (You can determine it with this free calculator.)
But if work and other factors won't allow you to stay up till 2 a.m. and sleep in until 10 a.m., could you push yourself to become an early bird?
'Some studies showed that intensive intervention could help change your chronotype… but only by a few hours,' Wenzler says. 'But forcing yourself to get up early every day while you are an extreme evening person will not make you a morning person. In these cases, it might be best to adapt your life, as much as possible, to your chronotype.'
Walker also noted that only slight shifts are really possible, and that the ongoing, disciplined interventions that are required to truly change chronotypes are 'just not tenable,' he said. 'Let night owls sleep as they were biologically designed. At least, that's how I feel on the basis of the science and medicine of the data.'
So, is the cognitive health of night owls just simply doomed?
'If these individuals are doomed is hard to say, as we only had a follow-up of 10 years,' says Wenzler, explaining that the true long-term effects—particularly whether or not night owls are more likely to develop dementia—need further investigation.
'Faster cognitive decline in middle age does not necessarily mean a higher risk of dementia,' she said in the news release. 'With our research, we hope to find out more about this. This will ultimately help us to be able to give people informed advice on how to try to prevent dementia.'
More on cognitive health:
5 ways to reduce your dementia risk as study estimates U.S. cases could double by 2060
A study on the Mediterranean diet offers the strongest proof yet that it's associated with healthy brain aging
It's not just forgetfulness: 8 early warning signs of dementia
This story was originally featured on Fortune.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

I'm eyeing these 32 best back-to-school shoe sales from Hoka, Crocs, Adidas and more
I'm eyeing these 32 best back-to-school shoe sales from Hoka, Crocs, Adidas and more

CNN

timean hour ago

  • CNN

I'm eyeing these 32 best back-to-school shoe sales from Hoka, Crocs, Adidas and more

One routine I always looked forward to when returning to elementary school, high school or college was shoe shopping. Normally, I'd only pick out a stylish sneaker and a running shoe to replace the worn-out kicks I'd run down, but with today's back-to-school deals across brands like Hoka, Crocs, Nike and more, you may want to stray and snag multiple pairs. Coming from someone who covers sales and deals for a living, I curated the best back-to-school sales, so you can optimize your haul (and potentially spend leftover cash on clothing too). The German-founded brand synonymous with its three-stripe marked running shoes and sneakers is offering up to 40% off as part of its back-to-school sale. Adidas Women's Gazelle Bold Shoes Give your ensembles a bit more height with these rubber gum sole, platform street sneakers. Starting at $84, they come in vivid color combinations and neutral designs like this tan suede with maroon accents. Adidas Ultraboost 1.0 Shoes Striking a great balance of comfort and versatility, these cushy sneakers work for low-impact activities. They're discounted in men's and women's our review Adidas Women's VL Court 3.0 Shoes Closely resembling the popular Sambas, the VL Court 3.0 shoes tap into the same aesthetics but provide more cushion through the sole. My sister owns this blue pair, and I can't help but steal them from time to time. Adidas Men's Grand Court 2.0 Shoes If you prefer a more streamlined, classic shoe, it doesn't get more so than the Grand Court 2.0. They're emblazoned with the brand's iconic stripes, and they pair well with anything from jeans to shorts. In prep for the busy school season ahead, the major footwear retailer kicked off its Big-Deal Brands, offering up to 25% off New Balance, Crocs, Reebok, Hey Dude and more. Plus, if you're stocking up on multiple pairs, unlock free shipping on orders $75 and up with code FREESHIP. Reebok Women's Club C 85 Sneakers Leaning into retro aesthetics, the popular Club Cs make a great go-to white sneaker. Style them with a pair of baggy jeans to let their low profile peek out underneath. A bonus: They're marked down by $20 at DSW. Crocs Women's Dylan Clogs These platform clogs may be a little out there, but they became fast favorites among our editors. They adopt a faux leather texture that make them look more expensive than their under-$50 sale price. New Balance Men's CT300 v3 Court Sneakers While New Balance is known for their on-trend Dad sneakers, they also offer more streamlined Court sneakers that add a fun touch to 'fits. Take this discounted pair for example. Hey Dude Men's Welsh Grip Boat Shoes We've been seeing Hey Dudes crop up more and more. So if you're heading to a college with warmer temps year-round, these boat shoes suit those subtropical regions well. From Dad sneakers to shoes for girls and boys, New Balance can outfit your entire family for the back-to-school season. A few select styles and colors are on sale, so I've done the vetting for you, allowing you to check off your supply list next. New Balance 1906R Sneakers Available in half sizes for men and women, these sneakers are a crowd pleaser. I appreciate its chrome accents and intertwining lines, which lend it a retro feel. New Balance 2002R Shoes From purple palettes to moss green pairs like this one, the 2002Rs are on sale in a variety of options. They make a good go-to sneaker to throw on as you trek across campus. New Balance 471 Shoes Make your mark on the first day of school with these statement-making shoes. They feature a colorful fuzz with suede overlays that help them standout. New Balance Kid's FuelCell Play Bungee Shoes Tons of kid's styles are 25% off with code NBLEARN. That includes these sneakers with an easy bungee-cord lace and velcro strap. Save up to 50% during Nike's back-to-school sale when you use code SPORT, which stacks an extra 20% off select on-sale styles like Nike Air Force 1s and Nike Dunks. Nike Women's Air Max Excee Shoes Inspired by the bestselling Nike Air Max 90, the Excees reinvents the classic shoe adds an elongate toe and contrasting lines on the upper. For those who may be in between sizes can choose from half sizes. Nike Women's V2K Run Shoes My sister owns these Nike sneakers, so I've gotten to see the silver accent details in person. I love that the added chromed elevates an otherwise plain chunky sneaker. They're ideal for running errands or getting you from class to class. Nike Women's Dunk Low Retro Shoes These eye-catching Dunks will certainly turn heads on campus. The titular street sneakers comes in men's and women's sizes as well as an array of color-blocked options for $100. Nike Men's Air Max 270 Shoes Whether you're hitting the campus gym, nailing the Pacer test or taking part in recreational sports, these shoes with a sock upper are designed to feel lightweight and airy on your feet. A new school year means new deals. You'll find discounts sitewide at Nordstrom Rack, bringing fresh savings on popular name brands. That spans comfy sneakers from Adidas and Vans to running shoes from Hoka and Brooks. Hoka Women's Challenger 7 Running Shoes Hoka running shoes have won over our expert testers time and time again. If you're looking to invest in a pair of athletic shoes, look no further than these Challenger 7s on sale at Nordstrom Rack. Birkenstock Women's Boston Cord Clogs My Boston Clogs have served me well. I slide them on whenever I'm taking out the trash, checking the mail or doing laundry. Nordstrom Rack has this cute red corduroy pair for $100. Vans Men's Asher Sneakers Skaters and students alike can reach for this pair of discounted Vans. They adopt a brown checkered pattern that brings more visual interest than the typical white and black options we see. Brooks Men's Revel 7 Hybrid Running Shoes I'm an owner of two Brooks running shoes, and I much prefer them over other brands out there. Like the pairs I own, these feature a thick, bouncy sole and mesh upper to keep your steps altogether breathable and comfy. Calling all teachers or aspiring professionals: Rothy's Final Few Sale is filled with Mary Janes, loafers, ballet flats and more. Be ready to take on interviews and presentations while looking polished and feeling confident with the brand's comfortable footwear. Rothy's The Double Buckle Mary Janes You can't go wrong with a Mary Jane. These feature a pair of secure buckles and a square toebox, toeing the line of sophisticated and comfortable. Rothy's The Loafer in Ecru These no-frills loafers pair well with just about anything in its on-sale tan color. It's made with a flexible upper that won't hinder your steps throughout the day. Rothy's The Double Bit Drivers Incorporating a horsebit detail, these drivers exude luxurious. Choose from four on-sale options, like refined checkered patterns and versatile plain colors. Rothy's The Point II Flats Bring a bit more fun to 'fits with these signature ballet flats that come in discounted flower patterns and pastel colors. Their pointed toe peeps out from under long hems. One of our favorite outdoor apparel retailers is hosting its slate of footwear deals, timed perfectly for the busy shopping season. On top of hiking boots and trail shoes, running shoes, sandals and more are also marked down at REI. Keen Women's Newport H2 Sandals If you prefer wearing comfortable sandals to and fro, these activewear shoes keep feet on lock and your tread slip-free. Score four different colors for under $100. Teva Men's Universal Trail Sandals A classic men's sandal for any water adventures, these Tevas will come in handy whenever you have downtime and are attending school on the coast. Merrell Women's Speed Eco Hiking Shoes Hit the trails in between study sessions or during long weekends with one of the most stylish hiking shoes I've come across. Even better, they just dropped below $85 at REI. Merrell Men's Moab Edge 3 Hiking Shoes Go sport mode with these adventure-ready hiking shoes from Merrell. They boast a shock-absorbing lug sole and a breathable mesh liner. Tick off your back-to-school footwear checklist while sandals, sneakers, ballet flats and more are discounted at the shoe destination. Zappos is also exclusively knocking down prices on Crocs and Converse. Converse Chuck Taylor All Star High-Top Sneakers When I think of the back-to-school shoe, it's Converse. These classic high-tops never go out of style. Available in a variety of on-sale options, you can pick a fun pop of color to liven up your closet. Crocs Classic Clogs Hitting the dorm showers? Rule number one is to bring a good pair of shower shoes. These Crocs hold up to water and rinse easily. Their bouncy EVA construction and heel strap also helps deliver better stability. On Running Women's Cloudeclipse Shoes Those who have goals to up their step or running count may appreciate these On Running shoes. They tout a design made for interval training on hard, pavement surfaces. New Balance Classics 574 Shoes If you like the vintage look, these New Balance 574s for their pointed silhouette, rubber details and mixed textures. It's discounted in over 10 colors so you can really take your pick based on what suits your wardrobe. One of the best times to snag new footwear is during the back-to-school season. Retailers know that parents and kids alike will be flocking to different apparel brands to revamp their wardrobes for the season ahead. In kind, many destinations, specifically large retailers like DSW, Nordstrom Rack and Zappos, reliably knock down prices on a selection of shoes, typically fashionable sneakers and running shoes. You'll find that most of the affordable picks above fall under $100. Our deals team has over a decade of combined commerce journalism experience. Rikka Altland, Jacqueline Saguin and Elena Matarazzo source the deals for the day each morning to curate one-offs and retailer-specific roundups of the best sales to shop. Searching everything from coveted pieces from Lululemon to the best picks from Target's back-to-school sale, the team works across a wide variety of categories to ensure we're finding the best buys for our readers.

Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO

Yahoo

time2 hours ago

  • Yahoo

Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO

Novo Nordisk (NVO) reported an earnings miss Wednesday, sending its stock down 4% in early trading, pressuring the stock further after a surprise management shake-up earlier in the year and sharply lowered guidance despite growing sales of its blockbuster GLP-1 drugs Ozempic and Wegovy. The stock is down more than 46% year to date as a result. CFO Karsten Munk Knudsen discussed some of the changes in recent weeks. He told Yahoo Finance that the leadership change — the ousting of CEO Lars Jørgensen and international head Mike Doustdar taking his place — was a surprise. "I was surprised about the changes of CEOs back in May," Knudsen said. "But ... looking at other companies ... when pressure is on, in terms of performance and competition, then it's not unusual that bosses and owners assess what's the right team to lead the company. In a macro setting I don't think its extraordinary, but in a Novo setting it was indeed surprising." The US market has also proven a challenge for Novo Nordisk, as it lost its lead despite a first-mover advantage to competitor Eli Lilly (LLY). Executives blame the compounding market, in which copycats are allowed under special circumstances, with telehealth platforms taking advantage of the loophole despite the FDA ending a shortage of GLP-1s that previously allowed copycats to freely sell on the market. Knudsen said the compounding market is about one-third of current GLP-1 prescriptions in the US market. On top of the competition and copycats, Novo Nordisk, like other big pharma names, has been targeted by the Trump administration to lower prices for consumers. It was one of 17 companies to receive a letter demanding lower costs for current and new products. "In reality, we're not that far apart in the sense that we also drive for affordable access in products that we supply. Our GLP-1 pricing is already rather low," Knudsen said, without revealing the actual numbers. Outgoing CEO Lars Jørgensen said on an earnings call Wednesday that its prices for Medicaid, for example, are already lower than in Europe. Those prices are not publicly available. The letter also asked the companies to price new drugs at the same low pricing found in other developed countries and to provide the lower cash prices more widely. Crunching cash numbers Some experts have expressed doubt about cash market success, however. Craig Garthwaite, a professor of strategy and healthcare at Northwestern University's Kellogg School of Management, posted on X in response to the Trump letters, questioning the strategy's viability. "How many customers do we believe have the ability (or willingness) to pay out of pocket for brand name drugs? A simple reading of the literature on increasing cost sharing suggests that people are not prepared to pay cash for these products — even if it is at the net and not the list price," Garthwaite said. But Knudsen noted that of its Wegovy patients in the US, 10% are paying cash through NovoCare, the direct-to-consumer channel, after it launched in March. "I am absolutely convinced that the cash channel is going to increase from here, and going to constitute a major part of the Wegovy business into the future," he said, adding that the overall cash market for GLP-1 in the US is already way above 10%. Knudsen referenced the compounding market, saying it provides insight into the potential, as those customers are cash-paying and represent one-third of the Wegovy market. But the cash price paid for copycats is significantly lower than the $499 per month available on NovoCare. Hims and Hers (HIMS), which Novo recently cut ties with over its refusal to stop selling compounded semaglutide, advertises prices as low as $199 per month for a 12-month plan of the copycat drug. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry
Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry

Yahoo

time3 hours ago

  • Yahoo

Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry

Booming Biologics and Biosimilars Market Drives Global Cell Line Development Surge; CDMOs and Technological Advancements Key to Growth Cell Line Development Market Dublin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The "Cell Line Development Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" has been added to offering. The Global Cell Line Development Market was valued at USD 7.5 billion in 2024 and is estimated to grow at a CAGR of 10.2% to reach USD 19.7 billion by 2034. Market expansion is being fueled by a growing focus on biologics and biosimilars, particularly as the pharmaceutical industry shifts toward personalized therapies and precision medicine. The surge in demand for monoclonal antibodies, vaccines, and recombinant proteins has placed strong emphasis on the development of highly stable and productive cell lines. The increase in chronic illnesses-such as autoimmune diseases, cancer, and infectious disorders-has led to the rising adoption of biologics, which depend heavily on well-characterized cell lines. This has also elevated the need for quality-controlled production systems. Contract development and manufacturing organizations (CDMOs) have contributed significantly to market momentum. Small and mid-sized biotech firms are increasingly outsourcing their cell line development to CDMOs to reduce overhead costs and accelerate timelines, benefiting from their technical expertise, scalable platforms, and regulatory compliance with agencies like the FDA. This trend allows companies to focus on core competencies such as research and innovation while leveraging CDMOs for end-to-end services including cell line screening, clone selection, process optimization, and GMP manufacturing. These partnerships also offer access to advanced technologies, streamlined workflows, and proven quality assurance frameworks, enabling faster entry into clinical trials and reducing risks associated with internal capacity limitations. The reagents and media segment generated USD 3.4 billion in 2024. This segment continues to dominate due to its central role in cell growth and maintenance across both R&D and production stages. With a notable increase in the use of mammalian cells for biologics manufacturing, the demand for high-efficiency reagents and cell culture media has surged. A growing preference for protein-free and serum-free media is helping the segment gain traction, offering improved scalability, reduced risk of contamination, and consistency in large-scale production environments. Such media types are essential for regulatory approval and efficiency in biologics manufacturing, which demands stringent process control. In terms of cell type, the mammalian cells segment generated the highest revenue in 2024, accounting for 71.4%. Their dominance is linked to their superior ability to express human-compatible therapeutic proteins with accurate post-translational modifications. Widely used cell lines such as CHO and HEK-293 are favored in biologics production due to their robust protein folding, glycosylation, and scalability. Technological progress in gene editing tools, such as CRISPR-Cas9, combined with automation and high-throughput systems, continues to enhance the speed and stability of mammalian cell line development, further reinforcing their leadership in the market. The United States Cell Line Development Market was valued at USD 2.6 billion in 2024, driven by a combination of advanced biopharma infrastructure, high rates of chronic disease, and strong adoption of cutting-edge biologic therapies. The country's well-established pharmaceutical ecosystem, which includes top-tier biotech firms and extensive R&D investment, plays a pivotal role in expanding the market. Research institutions and innovation hubs across the US are also accelerating technological advancements in gene editing and automated platforms, leading to faster and more efficient development cycles. Government and private sector funding are also propelling innovation, further supporting the country's leadership in the field. Key companies operating in the Global Cell Line Development Market include PromoCell, Novartis, Genscript Biotech, Sartorius, Thermo Fisher Scientific, ProBioGen, Cytiva (Danaher Corporation), ASIMOV, Advanced Instruments, Sigma Aldrich (Merck KGaA), Eurofins Scientific, WuXi AppTec, Aragen Life Sciences, Fyonibio, and Lonza Group. Top-tier players in the cell line development space are heavily investing in technological innovations like automated cell screening platforms, single-use bioreactors, and CRISPR-based genome editing. Many companies are forming strategic alliances with biotech firms and CDMOs to enhance service offerings and expand production capabilities. Acquisitions are also a popular move to integrate novel technologies or gain regional access. Firms are focusing on R&D to develop serum-free and chemically defined media, helping improve regulatory compliance and scalability. Comprehensive Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis Key Attributes Report Attribute Details No. of Pages 145 Forecast Period 2024-2034 Estimated Market Value (USD) in 2024 $7.5 Billion Forecasted Market Value (USD) by 2034 $19.7 Billion Compound Annual Growth Rate 10.2% Regions Covered Global Key Topics CoveredChapter 1 Methodology and ScopeChapter 2 Executive Summary2.1 Industry 360 synopsis2.2 Key market trends2.2.1 Regional2.2.2 Products & services2.2.3 Source2.2.4 Cell line2.2.5 Application2.2.6 End use2.3 CXO perspectives: Strategic imperatives2.3.1 Key decision points for industry executives2.3.2 Critical success factors for market players2.4 Future outlook and strategic recommendationsChapter 3 Industry Insights3.1 Industry ecosystem analysis3.1.1 Supplier landscape3.1.2 Value addition at each stage3.1.3 Factors affecting the value chain3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Growing vaccine production worldwide3.2.1.2 Increasing prevalence of cancer across the globe3.2.1.3 Technological innovations in cell line development3.2.1.4 Growing biotechnology industry3.2.2 Industry pitfalls and challenges3.2.2.1 Complex regulatory landscape3.2.2.2 Challenges related to stem cell research3.2.3 Market opportunities3.2.3.1 Emerging applications in personalized medicine and regenerative therapies3.2.3.2 Adoption of artificial intelligence in cell line optimization3.3 Growth potential analysis3.4 Regulatory landscape3.4.1 North America3.4.2 Europe3.4.3 Asia Pacific3.4.4 Latin America3.4.5 Middle East and Africa3.5 Future market trends3.6 Emerging therapeutic applications of CHO cell lines3.7 Technology landscape3.7.1 Current technological trends3.7.2 Emerging technologies3.8 Porter's analysis3.9 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Key developments4.6.1 Merger and acquisition4.6.2 Partnership and collaboration4.6.3 New product launches4.6.4 Expansion plansChapter 5 Market Estimates and Forecast, By Products & Services, 2021 - 2034 ($ Mn)5.1 Key trends5.2 Reagents and media5.3 Equipment5.3.1 Incubator5.3.2 Centrifuges5.3.3 Bioreactors5.3.4 Storage equipment5.3.5 Microscopes5.3.6 Electroporators5.3.7 Fluorescence-activated cell sorting5.3.8 Other equipment5.4 Accessories and consumables5.5 ServicesChapter 6 Market Estimates and Forecast, By Source, 2021 - 2034 ($ Mn)6.1 Key trends6.2 Mammalian6.2.1 Chinese Hamster Ovary (CHO)6.2.2 Human Embryonic Kidney (HEK)6.2.3 Baby Hamster Kidney (BHK)6.2.4 Murine myeloma6.2.5 Other mammalian sources6.3 Non-mammalian6.3.1 Insects6.3.2 AmphibiansChapter 7 Market Estimates and Forecast, By Cell Line, 2021 - 2034 ($ Mn)7.1 Key trends7.2 Recombinant7.3 Hybridomas7.4 Continuous cell lines7.5 Primary cell linesChapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)8.1 Key trends8.2 Bioproduction8.3 Drug discovery8.4 Toxicity testing8.5 Tissue engineering8.6 ResearchChapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)9.1 Key trends9.2 Pharmaceutical and biotechnology companies9.3 Academic and research institutes9.4 Contract research organizations (CROs)Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)10.1 Key trends10.2 North America10.2.1 U.S.10.2.2 Canada10.3 Europe10.3.1 Germany10.3.2 UK10.3.3 France10.3.4 Italy10.3.5 Spain10.3.6 Netherlands10.4 Asia Pacific10.4.1 China10.4.2 Japan10.4.3 India10.4.4 Australia10.4.5 South Korea10.5 Latin America10.5.1 Brazil10.5.2 Mexico10.6 Middle East and Africa10.6.1 South Africa10.6.2 Saudi Arabia10.6.3 UAEChapter 11 Company Profiles11.1 Advanced Instruments11.2 Aragen Life Sciences11.3 ASIMOV11.4 Cytiva (Danaher Corporation)11.5 Eurofins Scientific11.6 Fyonibio11.7 Genscript Biotech11.8 Lonza Group11.9 Novartis11.10 ProBioGen11.11 PromoCell11.12 Sartorius11.13 Sigma Aldrich (Merck KGaA)11.14 Thermo Fisher Scientific11.15 WuXi AppTecFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cell Line Development Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store